

Jesus Garcia-Foncillas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6028397/publications.pdf>

Version: 2024-02-01

196
papers

9,516
citations

81743

39
h-index

40881

93
g-index

203
all docs

203
docs citations

203
times ranked

14991
citing authors

#	ARTICLE	IF	CITATIONS
1	Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents. <i>New England Journal of Medicine</i> , 2000, 343, 1350-1354.	13.9	2,323
2	Epigenetic regulation of microRNA expression in colorectal cancer. <i>International Journal of Cancer</i> , 2009, 125, 2737-2743.	2.3	418
3	microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 2281-2290.	3.2	328
4	miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. <i>Carcinogenesis</i> , 2009, 30, 1903-1909.	1.3	314
5	A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. <i>Neuro-Oncology</i> , 2014, 16, 520-527.	0.6	298
6	Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidilate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1779-1786.	0.8	296
7	MicroRNA-451 Is Involved in the Self-renewal, Tumorigenicity, and Chemoresistance of Colorectal Cancer Stem Cells. <i>Stem Cells</i> , 2011, 29, 1661-1671.	1.4	248
8	Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. <i>Genome Biology</i> , 2013, 14, R104.	13.9	224
9	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
10	Down-Regulation of <i>hsa-miR-10a</i> in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. <i>Molecular Cancer Research</i> , 2008, 6, 1830-1840.	1.5	208
11	Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas. <i>PLoS ONE</i> , 2011, 6, e26740.	1.1	187
12	Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. <i>Cell Research</i> , 2008, 18, 823-833.	5.7	174
13	miR-192/miR-215 Influence 5-Fluorouracil Resistance through Cell Cycle-Mediated Mechanisms Complementary to Its Post-transcriptional Thymidilate Synthase Regulation. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2265-2275.	1.9	154
14	Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 1659-1669.	1.4	141
15	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications. <i>Oncotarget</i> , 2017, 8, 18456-18485.	0.8	134
16	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
17	Obesity and colorectal cancer: molecular features of adipose tissue. <i>Journal of Translational Medicine</i> , 2016, 14, 21.	1.8	133
18	Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2003, 64, 28-35.	0.9	126

#	ARTICLE	IF	CITATIONS
19	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 849.	1.3	117
20	PP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potential. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 938-947.	1.9	109
21	Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. <i>Journal of Clinical Medicine</i> , 2017, 6, 29.	1.0	88
22	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. <i>Oncotarget</i> , 2015, 6, 4299-4314.	0.8	87
23	Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: Implications in cancer therapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1753-1763.	1.2	74
24	TWIST1 Overexpression is Associated with Nodal Invasion and Male Sex in Primary Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 78-87.	0.7	68
25	Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2012, 48, 1774-1780.	1.3	67
26	Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 282.	1.8	66
27	Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. <i>Oncotarget</i> , 2016, 7, 47954-47965.	0.8	66
28	Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 159-170.	3.2	65
29	Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 347-356.	3.2	63
30	Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018, 119, 1464-1470.	2.9	62
31	Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 194-202.	1.9	60
32	Î±-MSH regulates interleukin-10 expression by human keratinocytes. <i>Archives of Dermatological Research</i> , 1998, 290, 425-428.	1.1	54
33	Prognostic implications of miR-16 expression levels in resected non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2011, 103, 411-415.	0.8	52
34	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. <i>Clinical and Translational Oncology</i> , 2010, 12, 533-542.	1.2	51
35	Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 4155-4166.	3.2	47
36	KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. <i>Cells</i> , 2020, 9, 219.	1.8	46

#	ARTICLE	IF	CITATIONS
37	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020, 6, 1461-1471.	0.8	44
38	A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. <i>Oncology Reports</i> , 2007, 17, 1089-94.	1.2	44
39	Synthesis and biological evaluation of new symmetrical derivatives as cytotoxic agents and apoptosis inducers. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2031-2044.	1.4	42
40	MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2015, 30, 899-906.	1.0	41
41	Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. <i>British Journal of Haematology</i> , 1997, 98, 418-425.	1.2	39
42	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2015, 51, 423-430.	0.8	39
43	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for <i>RAS</i> Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. <i>Clinical Cancer Research</i> , 2021, 27, 2515-2522.	3.2	39
44	Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. <i>Oral Oncology</i> , 2007, 43, 713-719.	0.8	38
45	Growth and growth hormone secretion in children with cancer treated with chemotherapy. <i>Journal of Pediatrics</i> , 1997, 131, 105-112.	0.9	36
46	Characterization of cisplatin cytotoxicity delivered from PLGA-systems. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 68, 503-512.	2.0	36
47	Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma. <i>Cancer</i> , 1998, 83, 889-895.	2.0	35
48	Irinotecan, Oxaliplatin, and 5-Fluorouracil/Leucovorin Combination Chemotherapy in Advanced Colorectal Carcinoma: A Phase II Study. <i>Clinical Colorectal Cancer</i> , 2002, 2, 104-110.	1.0	35
49	Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. <i>World Journal of Gastroenterology</i> , 2012, 18, 637.	1.4	35
50	Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 5903-5917.	0.8	35
51	The Role of MicroRNAs in Hepatoblastoma Tumors. <i>Cancers</i> , 2019, 11, 409.	1.7	35
52	Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1823-1829.	1.8	34
53	EphB2 stem-related and EphA2 progression-related miRNA-based networks in progressive stages of CRC evolution: clinical significance and potential miRNA drivers. <i>Molecular Cancer</i> , 2018, 17, 169.	7.9	34
54	Proteomic analysis in cancer research: potential application in clinical use. <i>Clinical and Translational Oncology</i> , 2006, 8, 250-261.	1.2	33

#	ARTICLE	IF	CITATIONS
55	Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. <i>Oncology Reports</i> , 2007, 17, 325-8.	1.2	33
56	Targeting the RAS-dependent chemoresistance: The Warburg connection. <i>Seminars in Cancer Biology</i> , 2019, 54, 80-90.	4.3	31
57	Four-Week Neoadjuvant Intensity-Modulated Radiation Therapy With Concurrent Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer Patients: A Validation Phase II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 587-593.	0.4	30
58	A new palliative care consultation team at the oncology department of a university hospital: an assessment of initial efficiency and effectiveness. <i>Supportive Care in Cancer</i> , 2012, 20, 2199-2203.	1.0	29
59	Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 2289-2302.	1.2	27
60	New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2468.	1.8	27
61	Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer. <i>Theranostics</i> , 2021, 11, 3595-3606.	4.6	27
62	Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. <i>Marine Drugs</i> , 2015, 13, 3276-3286.	2.2	25
63	Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?. <i>BioMed Research International</i> , 2016, 2016, 1-13.	0.9	25
64	Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review. <i>Current Medical Research and Opinion</i> , 2016, 32, 1137-1141.	0.9	25
65	UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition. <i>Journal of Clinical Medicine</i> , 2019, 8, 560.	1.0	25
66	Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 346.	1.0	25
67	Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2009, 32, 580-584.	1.1	24
68	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 74, 193-202.	2.0	24
69	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 162-178.	1.2	24
70	DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. <i>BMC Cancer</i> , 2014, 14, 965.	1.1	24
71	MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 878.	1.8	24
72	Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1696-1707.	1.9	24

#	ARTICLE	IF	CITATIONS
73	Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments. <i>Cancers</i> , 2021, 13, 3209.	1.7	24
74	Chemotherapy-induced growth hormone deficiency in children with cancer. <i>Medical and Pediatric Oncology</i> , 1995, 25, 90-95.	1.0	23
75	CD24 expression on human keratinocytes. <i>Experimental Dermatology</i> , 1998, 7, 175-178.	1.4	23
76	Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). <i>Clinical and Translational Oncology</i> , 2012, 14, 726-739.	1.2	23
77	Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 742-748.	0.5	23
78	A Novel Missense Mutation in the CYLD Gene in a Spanish Family With Multiple Familial Trichoepithelioma. <i>Archives of Dermatology</i> , 2007, 143, 1209-10.	1.7	22
79	Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. <i>Journal of Surgical Oncology</i> , 2014, 110, 484-485.	0.8	22
80	Precision oncology: a clinical and patient perspective. <i>Future Oncology</i> , 2021, 17, 3995-4009.	1.1	22
81	N -Acetylcysteine downregulates vascular endothelial growth factor production by human keratinocytes in vitro. <i>Archives of Dermatological Research</i> , 2000, 292, 621-628.	1.1	21
82	Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 40169-40180.	0.8	20
83	Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?. <i>World Journal of Gastroenterology</i> , 2017, 23, 377.	1.4	20
84	Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2015, 15, 132.	0.8	19
85	Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1729-1736.	1.6	19
86	The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. <i>Cancers</i> , 2021, 13, 322.	1.7	19
87	The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. <i>BioMed Research International</i> , 2016, 2016, 1-8.	0.9	18
88	Cross Talk between Wnt/ β -Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. <i>Molecular and Cellular Biology</i> , 2016, 36, 1734-1739.	1.1	18
89	Development of a DNA Microelectrochemical Biosensor for CEACAM5 Detection. <i>IEEE Sensors Journal</i> , 2010, 10, 1368-1374.	2.4	17
90	Differential modulation of IL-8 and TNF-alpha expression in human keratinocytes by buflomedil chlorhydrate and pentoxifylline. <i>Experimental Dermatology</i> , 1997, 6, 186-194.	1.4	16

#	ARTICLE	IF	CITATIONS
91	Patterns of Response After Preoperative Treatment in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 698-704.	0.4	16
92	Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche. <i>International Journal of Colorectal Disease</i> , 2014, 29, 885-885.	1.0	16
93	Caveolin-1 is Markedly Downregulated in Patients with Early-Stage Colorectal Cancer. <i>World Journal of Surgery</i> , 2017, 41, 2625-2630.	0.8	16
94	UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. <i>PLoS ONE</i> , 2017, 12, e0182044.	1.1	16
95	Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. <i>JCO Global Oncology</i> , 2020, 6, 1357-1362.	0.8	16
96	A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 2135.	1.4	16
97	Gene Expression Profile of Ewing Sarcoma Cell Lines Differing in Their EWS-FLI1 Fusion Type. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 537-542.	0.3	15
98	Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy. <i>Pathology Research and Practice</i> , 2016, 212, 1133-1137.	1.0	15
99	The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1275.	1.0	15
100	Functional and Clinical Impact of CircRNAs in Oral Cancer. <i>Cancers</i> , 2020, 12, 1041.	1.7	15
101	The clinical impact of using complex molecular profiling strategies in routine oncology practice. <i>Oncotarget</i> , 2018, 9, 20282-20293.	0.8	15
102	Analysis of BRCA1 and mtDNA haplotypes and mtDNA polymorphism in familial breast cancer. <i>Mitochondrial DNA</i> , 2015, 26, 227-231.	0.6	14
103	MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. <i>Cancers</i> , 2020, 12, 1655.	1.7	14
104	Hematological Response of Topotecan in Tumor-Bearing Rats: Modeling of the Time Course of Different Cellular Populations. <i>Pharmaceutical Research</i> , 2004, 21, 567-573.	1.7	13
105	PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer. <i>Tumor Biology</i> , 2015, 36, 5753-5755.	0.8	13
106	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2780-2790.	1.9	13
107	Molecular evidence of field cancerization initiated by diabetes in colon cancer patients. <i>Molecular Oncology</i> , 2019, 13, 857-872.	2.1	13
108	MicroRNAs in Rectal Cancer: Functional Significance and Promising Therapeutic Value. <i>Cancers</i> , 2020, 12, 2040.	1.7	13

#	ARTICLE	IF	CITATIONS
109	The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 1108.	1.7	13
110	16-Year Experience at M. D. Anderson Cancer Center with Primary Ki-1 (CD30) Antigen Expression and Anaplastic Morphology in Adult Patients with Diffuse Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 20, 97-102.	0.6	12
111	Activity of Gefitinib in Central Nervous System Metastases in Patients with Non-Small-Cell Lung Cancer: Two Case Reports and a Review of the Literature. <i>Clinical Lung Cancer</i> , 2005, 7, 138-140.	1.1	12
112	Synthesis and Biological Evaluation of 2,4,6-Trifluoromethyl-5-(pyridin-2-yl)pyrimidines as Cytotoxic Agents and Apoptosis Inducers. <i>Archiv Der Pharmazie</i> , 2008, 341, 28-41.	2.1	12
113	Potential therapeutic value of miR-425-5p in metastatic colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2213-2214.	1.6	12
114	Structural characteristics of novel symmetrical diaryl derivatives with nitrogenated functions. Requirements for cytotoxic activity. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1942-1948.	1.4	11
115	A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). <i>Investigational New Drugs</i> , 2011, 29, 1038-1044.	1.2	11
116	KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. <i>Oncology Letters</i> , 2013, 6, 1343-1345.	0.8	11
117	Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study. <i>BMC Cancer</i> , 2016, 16, 519.	1.1	11
118	Potential Therapeutic Impact of miR-145 Downregulation in Colorectal Cancer. <i>Molecular Therapy</i> , 2018, 26, 1399-1400.	3.7	11
119	Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2021, 13, 1456.	1.7	11
120	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. <i>JAMA Network Open</i> , 2021, 4, e2116536.	2.8	11
121	The Essentials of Multiomics. <i>Oncologist</i> , 2022, 27, 272-284.	1.9	11
122	Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. <i>Journal of Neuro-Oncology</i> , 2005, 73, 189-198.	1.4	10
123	Downregulation of miR-138 as a Contributing Mechanism to Lcn2 Overexpression in Colorectal Cancer with Liver Metastasis. <i>World Journal of Surgery</i> , 2016, 40, 1021-1022.	0.8	10
124	PP2A regulates signaling through hormonal receptors in breast cancer with important therapeutic implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 435-438.	3.3	10
125	Cancer and suicidal ideation and behaviours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e020463.	0.8	10
126	The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1252.	1.0	10

#	ARTICLE	IF	CITATIONS
127	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 64, 124-126.	0.9	9
128	Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction. <i>Molecular Oncology</i> , 2019, 13, 1887-1897.	2.1	9
129	CAR-T cell and Personalized Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 131-145.	0.8	9
130	Symmetrical Derivatives with Nitrogenated Functions as Cytotoxic Agents and Apoptosis Inducers. <i>Letters in Drug Design and Discovery</i> , 2005, 2, 341-354.	0.4	8
131	Synthesis and Biological Evaluation of Heteroaryldiamides and Heteroaryldiamines as Cytotoxic Agents, Apoptosis Inducers and Caspase-3 Activators. <i>Archiv Der Pharmazie</i> , 2006, 339, 182-192.	2.1	8
132	Clinical Value of miR-26b Discriminating Ulcerative Colitis-associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	8
133	Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. <i>Journal of Pain Research</i> , 2019, Volume 12, 2349-2358.	0.8	8
134	Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study. <i>Neuroendocrinology</i> , 2020, 110, 50-62.	1.2	8
135	Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients. <i>Cancers</i> , 2021, 13, 1246.	1.7	8
136	Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes. , 2021, 9, e001705.		8
137	Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2014, 29, 641-641.	1.0	7
138	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. <i>Clinical and Translational Oncology</i> , 2012, 14, 835-841.	1.2	6
139	PP2A plays a key role in inflammation and cancer through tristetraprolin activation. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e11-e11.	0.5	6
140	Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. <i>JCO Oncology Practice</i> , 2020, 16, e298-e305.	1.4	6
141	Association between a specific miRNA signature and pathological response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14057-e14057.	0.8	6
142	Phase II Evaluation of Doxorubicin, Ifosfamide, and Dacarbazine Plus Amphotericin B in the Treatment of Metastatic Soft Tissue Sarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 332-337.	0.6	5
143	A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 219-220.	1.1	5
144	Clinical Impact and Regulation of the circCAMSAP1/ miR-328-5p/E2F1 Axis in Colorectal Cancer. <i>Molecular Therapy</i> , 2020, 28, 1387-1388.	3.7	5

#	ARTICLE	IF	CITATIONS
145	MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 2419.	1.0	5
146	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 563-576.	1.6	5
147	Colon cancer modulation by a diabetic environment: A single institutional experience. <i>PLoS ONE</i> , 2017, 12, e0172300.	1.1	5
148	Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 77-82.	1.2	4
149	Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients. <i>World Journal of Surgery</i> , 2018, 42, 3771-3778.	0.8	4
150	Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas. <i>Neuroendocrinology</i> , 2021, 111, 146-157.	1.2	4
151	Early Imaging and Molecular Changes with Neoadjuvant Bevacizumab in Stage II/III Breast Cancer. <i>Cancers</i> , 2021, 13, 3511.	1.7	4
152	Endometrial adenocarcinoma in one horn of a didelphic uterus with vaginal duplication. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013203280-bcr2013203280.	0.2	4
153	Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment. <i>Journal of Clinical Oncology</i> , 2012, 30, 4079-4079.	0.8	4
154	Patient Perspective on the Management of Cancer Pain in Spain. <i>Journal of Patient Experience</i> , 2020, 7, 1417-1424.	0.4	4
155	Ileal carcinoid tumor with liver metastases and cardiac involvement treated with intraarterial liposomal doxorubicin and valve replacement. <i>Clinical and Translational Oncology</i> , 2006, 8, 369-371.	1.2	3
156	A Semi-physiological-Based Pharmacokinetic/Pharmacodynamic Model to Describe the Effects of Topotecan on B-Lymphocyte Lineage Cells. <i>Pharmaceutical Research</i> , 2010, 27, 431-441.	1.7	3
157	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19447-19457.	1.8	3
158	Comment on Goldsworthy et al. Haploinsufficiency of the Insulin Receptor in the Presence of a Splice-Site Mutation in Ppp2r2a Results in a Novel Digenic Mouse Model of Type 2 Diabetes. <i>Diabetes</i> 2016;65:1434-1446. <i>Diabetes</i> , 2016, 65, e22-e23.	0.3	3
159	Deregulation of miR-92a in locally advanced rectal cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 612-612.	1.5	3
160	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. <i>Scientific Reports</i> , 2017, 7, 41371.	1.6	3
161	Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. <i>Pathology and Oncology Research</i> , 2019, 25, 269-278.	0.9	3
162	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020, 25, e1428-e1432.	1.9	3

#	ARTICLE	IF	CITATIONS
163	Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance. <i>Cancers</i> , 2021, 13, 3757.	1.7	3
164	MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2203.	1.8	3
165	Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers. <i>Cancers</i> , 2022, 14, 1793.	1.7	3
166	Comparative disease pattern of a patient with a novel BRCA2 truncation and knockout models for BRCA2. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 291-293.	1.1	2
167	Clinical significance of miR-126 in colorectal cancer. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 881-881.	1.5	2
168	Comment on "MicroRNA-199b-5p attenuates TGF- β 1-induced epithelial-mesenchymal transition in hepatocellular carcinoma". <i>British Journal of Cancer</i> , 2018, 118, 1028-1029.	2.9	2
169	Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients. <i>Cancers</i> , 2021, 13, 5003.	1.7	2
170	Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2008, 10, 372-374.	1.2	1
171	A novel BRCA1 mutation in a Spanish patient with ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 71-73.	1.1	1
172	Re: Role of Oncogenic K-Ras in Cancer Stem Cell Activation by Aberrant Wnt/ β -Catenin Signaling. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju196-dju196.	3.0	1
173	Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1249-1250.	1.2	1
174	Actualizaci3n de la recomendaci3n para la determinaci3n de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Espaola de Anatomaa Patol3gica y de la Sociedad Espaola de Oncologaa M3dica. <i>Revista Espanola De Patologia</i> , 2015, 48, 14-24.	0.6	1
175	Letter to the Editor: Is miR-199b-3p really involved in the migration ability of bone marrow mesenchymal stem cells?. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1067-1067.	1.5	1
176	Targeting PP2A to overcome enzalutamide resistance in AR+ breast tumors. <i>Endocrine-Related Cancer</i> , 2017, 24, L5-L6.	1.6	1
177	A Case Report Demonstrating the Potential Clinical Benefit of Exhaustive Molecular Profiling in an Aggressive Muscle-Invasive High-Grade Metastatic Urothelial Carcinoma. <i>Case Reports in Oncology</i> , 2017, 10, 493-500.	0.3	1
178	Potential contribution of SET and c-MYC deregulation to promote extracellular matrix remodelling in hepatocellular carcinoma. <i>British Journal of Pharmacology</i> , 2018, 175, 573-574.	2.7	1
179	Letter by Crist3bal et al Regarding Article, "Protein Phosphatase 2A Regulates Cardiac Na + Channels". <i>Circulation Research</i> , 2019, 124, e59.	2.0	1
180	Post-translational regulation could determine functional differences between α and β isoforms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 638-638.	1.2	1

#	ARTICLE	IF	CITATIONS
181	Clinical management patterns of advanced and metastatic gastroesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. <i>European Journal of Cancer Care</i> , 2020, 29, e13213.	0.7	1
182	Comment on "miR-199b-5p-DDR1-ERK signalling axis suppresses prostate cancer metastasis via inhibiting epithelial-mesenchymal transition". <i>British Journal of Cancer</i> , 2021, 125, 618-619.	2.9	1
183	Determina KRAS: A consolidated project.. <i>Journal of Clinical Oncology</i> , 2012, 30, 428-428.	0.8	1
184	Activation of angiogenic pathway in the prediction of pathologic response to bevacizumab-based neoadjuvant therapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10595-10595.	0.8	1
185	CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1610.	1.0	1
186	A new mutation in the hMSH2 gene in a Spanish Lynch syndrome family. <i>Clinical and Translational Oncology</i> , 2010, 12, 849-851.	1.2	0
187	A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation. <i>Oncology Letters</i> , 2011, 2, 807-809.	0.8	0
188	Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer. <i>World Journal of Surgery</i> , 2016, 40, 1017-1018.	0.8	0
189	Comment on "MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells". <i>British Journal of Cancer</i> , 2017, 116, e7-e7.	2.9	0
190	Dissecting the therapeutic implications of the complex SMAD4 regulatory network in metastatic colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1283-1284.	0.5	0
191	Relevance of the PP2A Pathway in the Molecular Mechanisms of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 658-659.	1.4	0
192	Therapeutic implications of the PP2A/MET signalling axis in doxorubicin-induced cardiotoxicity and antitumour properties. <i>British Journal of Pharmacology</i> , 2020, 177, 3850-3851.	2.7	0
193	Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications. <i>JCO Oncology Practice</i> , 2021, 17, e1162-e1169.	1.4	0
194	Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 145-145.	0.8	0
195	Role of polymorphic fc gamma receptor II/III in the efficacy of cetuximab in KRAS-NRAS-BRAF-PI3K mutated.. <i>Journal of Clinical Oncology</i> , 2012, 30, 477-477.	0.8	0
196	Overall survival (OS) of patients with TRK fusion-positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD).. <i>Journal of Clinical Oncology</i> , 2022, 40, 6579-6579.	0.8	0